Are new therapies in ER-positive breast cancer just the tip of the iceberg?

New therapies for breast cancer are now being based on older therapies such as those that are involved in estrogen blockade. As we understand more about this type of breast cancer, we learn that many of the growth pathways are in fact vast networks. If we block one pathway, cancer may find another way to continue growing. Just this year, Afinitor (everolimus), an mTOR inhibitor, was approved to work along with the aromatase inhibitor exemestane to block multiple pathways in advanced estrogen receptor-positive breast cancer. And this may be just the tip of the iceberg. For more on ER-positive breast cancer updates, stay tuned for the Fall 2012 issue of CURE magazine coming out in September!